The Under the Radar report suggests a profit of $4b for Retts and Fragile X during the orphan drug exclusivity period (7 years in the US, 10 years in Europe). Bell Potter estimates peak global sales of approx. US$3b per annum for Rett and Fragile X.
Ann: Annual Report to shareholders-NEU.AX, page-41
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
-0.620(2.99%) |
Mkt cap ! $2.567B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $3.535M | 176.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 358 | $20.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.12 | 318 | 7 |
View Market Depth
| Last trade - 14.45pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |